Is Trastuzumab a chemotherapy drug?

Trastuzumab (Trastuzumab) is not a chemotherapy drug. It is a targeted therapy drug that specifically acts on HER2-positive breast cancer cells to block their growth and division. Trastuzumab has a more specific target of action and generally has fewer systemic toxicities than chemotherapy drugs. Chemotherapy drugs mainly treat cancer by killing rapidly proliferating cancer cells, but they also affect normal, rapidly proliferating cells, such as bone marrow hematopoietic cells and digestive tract cells, leading to a series of adverse reactions.

Trastuzumab is classified as a targeted therapy drug, not a chemotherapy drug. It plays an important role in the treatment ofHER2-positive breast cancer and is often used in combination with other treatments, such as chemotherapy drugs, surgery, or radiotherapy, to achieve better therapeutic effects. Trastuzumab may cause serious or life-threatening reactions that may occur during administration or within 24 hours after administration. Trastuzumab may also cause serious lung damage.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The drug ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult the medical consultant. There is currently no generic drug of trastuzumab on the market.